Phase II Study: Ecstasy and post-traumatic stress disorder

Phase II Study: Ecstasy and post-traumatic stress disorder

MDMA or XTC may well provide relief to people suffering from post-traumatic stress disorder (PTSD). As we’ve posted before, small trial studies have shown the potentially beneficial effects when using ecstasy in a supervised manner and in conjunction with intense psychotherapy.

Now the phase-II study is well under way and the focus is on US war veterans that are heavily traumatized by the horrors they’ve seen during their tour of duty.

The study by the Multidisciplinary Association for Psychedelic Studies (MAPS) is performed in a clinic in Charleston, South Carolina. It aims to gain the approval to make MDMA a prescription medicine, though when –and if- this will happen remains uncertain, in light of all the taboos associated with XTC and psychedelics in general.

Current medication for distressed combat veterans includes antidepressants such as sertraline and paroxetine, which studies have shown to sometimes actually worsen depressions as opposed to non-medicated patients.

Rick Doblin, the director of MAPS, envisions a day when ecstasy can be picked up at the corner drug store.

Sources:
www.sciencedaily.com
www.motherboard.tv




Comments

    No comments yet, be the first.

Add comment

Nickname *
Message *
Humanoid check *
=
Please enter the calculation result in the box. This is used to prove you're a real flesh 'n blood human. If you can't see the image clearly, you can reload the page to get another image.
Last updated on 2014-04-23 | © 1999-2014 Azarius International

Azarius Office
PO box 3458
1001 AG Amsterdam
The Netherlands

Azarius Store
Kerkstraat 119
1017 GE Amsterdam
The Netherlands
Please send all mail to the Azarius office

Based on your IP address we have determined your current country.

This feature is used to see which products we can ship to your country.
Did our system screw up? Just change the country below.

For questions concerning our shipping policies, please see our FAQ page or contact us.